LAG3 and neoplasm: Treatment failure might be finally attributable to insufficient T-cell responses (transient, low avidity, low magnitude); poor T-cell homing to Mlh1−/− tumors, dysfunction or death of T cells within the tumor, and immune escape mediated by upregulation of immune-checkpoint molecules LAG-3 and PD-L1.